Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ciclopirox Nail Lacquer DTC Ads Should Be Avoided - FDA Advisory Cmte.

Executive Summary

Direct-to-consumer advertising of Hoechst Marion Roussel's ciclopirox nail lacquer treatment for onychomycosis should be avoided because of the narrow population for which the drug is effective, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee said Nov. 4.

You may also be interested in...

Penlac Must Be Part Of Comprehensive Management Program, Labeling Says

Aventis' Penlac nail lacquer must be used as part of a comprehensive management program in the treatment of fingernail and toenail fungus, labeling states.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts